A new focus on dermatology, ophthalmology, and gastroenterology will pave ways for many untapped opportunities that Viatris can utilize with its scale and manufacturing power. We believe Viatris is in ...

Viatris (VTRS) stock surges after Q3 earnings beat expectations with strong revenue growth and optimistic revenue outlook for ...

Drugmaker Viatris beat Wall Street estimates for third-quarter profit and revenue on Thursday, helped by strong demand for its new generic asthma and ADHD drugs, among others, sending its shares up 2.

A suit against Novartis and Vitaris by Henrietta Lacks’ estate hinges on questions about the morality and legality of using ...

Heritage is ponying up $10 million while Apotex is set to pay $39.1 million over the companies’ alleged roles in a sweeping ...

The patent office decision would allow Mylan immediately to return to the market across Europe. The generic product is now ...

But a generic version (and the active ingredient) of this popular medication, sildenafil, is widely available from several drug manufacturers at a fraction of the cost. Read on to find out more ...

Any Australian who has filled a prescription at the chemist will have been asked if they want a branded product or the generic version. And with consumers looking to cut costs wherever they can ...

Stuart Williams, chief legal officer for Mylan Pharmaceuticals, insists that the FDA decisions violate the Hatch-Waxman Act, and a court challenge seems likely. There's little doubt that the FDA ...

Oct 16 (Reuters) - Novartis (NOVN.S), opens new tab has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from ...

Availability of generic versions of antihypertensive drugs, insulin and chemotherapy has helped cut the high costs associated with brand-name drugs, making these treatments more accessible to more ...